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Abstract
Background: Mammographic breast density is a useful marker for breast cancer risk, as breast density is considered
one of the strongest breast cancer risk factors. The study objective was to evaluate and compare mammographic breast
density in infertile and parous women, as infertility may be associated with high breast density and cancer occurrence.
Methods: This study evaluated mammographic breast density using two different systems, BIRADS and Boyd. A
selected patient population of 151 women with primary infertility (case group) was compared to 154 parous women
who had at least one previous pregnancy (control group). Both groups were premenopausal women aged ≥35.
Results: Evaluation of mammographic features showed that 66.9 % of case group patients and 53.9 % of control group
patients were classified BIRADS-3/BIRADS-4; p < 0.05. Adjusted Odds ratio for the case group in the categories BIRADS-3/
BIRADS-4 was 1.78 (95 % CI: 1.10-2.89). Using the Boyd classification system, 53.6 % of case group patients and 31.8 % of
control group patients were classified E/F; p < 0.05. Adjusted Odds ratio for case group patients in Boyd categories E/F
was 2.05 (95 % CI: 1.07-3.93).
Conclusions: Both systems yielded a higher percentage of increased breast density in the case group. Boyd and BIRADS
classification systems indicate to what extend breast cancer lesions may be missed on mammography due to masking
by dense tissue. Therefore, patients with a high BIRADS or Boyd score should undergo further investigation.
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Background
Infertility is defined as the failure to conceive after one
year of regular unprotected intercourse, and prevalence
is approximately 10 %-15 % in Western countries [1].
The demand for infertility services is steadily increasing,
and so is the average age of women undergoing in vitro
fertilization (IVF) [2, 3]. Infertility treatments implying
medication and interventional procedures may modify
the hormonal environment and be cofactors in cellular
changes leading to cancer development [4, 5]. However,
few studies are reported on breast cancer risk in infertile
women who have undergone IVF treatment [6–8].
The association between breast cancer and infertility
has not been consistently studied, but it may be ex-
plained by hormonal disorders linked to infertility, a
different reproductive risk factor profile in infertile
women, or by a combination of these two factors.
Two decades ago, Sellers et al. reported a significantly
higher risk of developing breast cancer in nulliparous
married women who tried and failed to become preg-
nant [9]. Weiss et al. [10] found that among women with
a first full-term delivery at the age of 35 or older, fertility
problems were associated with a two-fold increased risk
of breast cancer. In contrast, Venn et al. [5] and Klip et
al. [8] summarized the association between infertility
and breast cancer and concluded that infertile women
did not appear to be at higher risk for breast cancer.
However, the possible influence of infertility itself on the
risk of breast cancer occurrence should be taken into
consideration [11].
The Italian National Federation for Breast Cancer
(FONCAM) guidelines 2005 recommend mammography
starting at 35 years in women who undergo hormone
therapy [12].
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At the Breast Unit of our institution (Policlinico
Umberto I, Rome), all women undergoing fertility treat-
ment are submitted to breast examination, and mam-
mography is performed according to the FONCAM
recommendations for women aged ≥35.
Mammographic breast density reflects the relative pro-
portion of glandular and stromal tissue to fatty tissue in
the breast. High breast density has been strongly associ-
ated with increased risk of breast cancer [13–15], and
this parameter could thus be a useful marker for breast
cancer risk and be considered one of the strongest risk
factors for breast cancer [15]. Breast density is often as-
sociated with reproductive and menstrual factors includ-
ing serum estrogen and progesterone concentrations
[16]. Furthermore, breast density is inversely correlated
with the accuracy of mammography and therefore a
measurement of density conveys information on the dif-
ficulty of detecting cancer in a mammogram.
In a previous study, we found that 68 % of women
with primary infertility had dense breast tissue according
to the BIRADS score compared with 37 % of premeno-
pausal women in a general population [17].
In the present study, two different systems, BIRADS
and Boyd, were employed to evaluate mammographic
breast density in two selected groups: a case group con-
sisting of infertile women and a control group consisting
of parous women. The results obtained in the two
groups were subsequently compared.
Methods
This study was carried out from January 2007 to
November 2009. Data collection methods and study de-
sign were approved by the institutional review board of
the University of Rome “Sapienza” and all patients signed
an informed consent form. The study included women
with primary infertility referred to our Breast Unit at the
Department of Gynaecology and Obstetrics, University of
Rome “Sapienza” as well as a control group selected from
the database of the Department of Radiology.
A total of 440 patients were referred to our Breast
Unit from the IVF Centre for a clinical breast examin-
ation before undergoing specific infertility treatment. Of
these patients, 51 % were >35 years old, 37 % had previ-
ously undergone fertility drug treatment and 9 % had
secondary infertility. Of the 440 patients, 151 (34 %)
were women aged >35 with primary infertility who had
never undergone fertility drug treatment (case group).
The case group was compared to a control group con-
sisting of 154 parous women selected from the database
of the Department of Radiology who had at least one
previous pregnancy (average 1.3 children per woman).
The control group patients had undergone mammog-
raphy examination for other reasons, such as family his-
tory or clinical suspicion of breast tumours, and they
were negative for cancer. The age range of the control
group was chosen in accordance with the case group:
premenopausal women age ≥35. The information col-
lected in both groups included: age, family history of
breast cancer with at least 2 first degree relatives, previ-
ous administration of hormonal contraceptive therapy
(HCT), age at menarche, previous pregnancy or etiology
of infertility (if known) as well as height and weight for
the calculation of body mass index (BMI). According to
the FONCAM recommendations, all recruited case
group patients underwent clinical examination and X-
ray mammography (XRM) after signing the informed
consent form. In all cases, conventional XRM was per-
formed at our Department of Radiological Science using
digital image formation and computed radiography. At
least two views per breast were obtained.
All mammograms were classified using BIRADS and
Boyd scales. Classification was carried out by three phy-
sicians (two radiologists and a breast specialist) blinded
to the clinical data in accordance with the guidelines of
the American College of Radiology (ACR) BIRADS.
Diagnostic quality of the mammograms was assessed ac-
cording to the PGMI evaluation system that includes
four image quality categories: P (perfect), G (good), M
(moderate) and I (inadequate).
BIRADS is a qualitative system, but the recently modi-
fied, more quantitative version was employed [18].
According to the BIRADS lexicon, patients were
assigned to one of the four categories of breast parenchy-
mal density distribution: BIRADS-1: the breast is almost
entirely fat (glandular parenchyma <25 % of the total area
of both breasts); BIRADS-2: scattered fibroglandular dens-
ities (25 %-50 %); BIRADS-3: heterogeneously dense
breast tissue (51 %-75 %); BIRADS-4: extremely dense
(>75 % glandular tissue). The Boyd scale is based on a
visual estimation of the proportion of mammographic
density in the projected area, divided into six categor-
ies of unequal intervals: type A: 0 %; type B: 0-10 %;
type C:10-25 %; type D: 25-50 %; type E: 50-75 % and
type F: >75 %. In case of contradictory judgments, the
classification assigned by at least two readers out of
three was considered correct.
Patients were excluded from the study if mammog-
raphy revealed focal disease, and/or if further diagnostic
tests such as breast ultrasound, breast magnetic reson-
ance or needle biopsy were required. To assess whether
classification as Dense Breast (DB) and Non Dense
Breast (NDB) was consistent, agreement between the
three referents was tested using Cohen’s kappa before
further statistical analysis. It was decided to divide BIR-
ADS into two categories and BOYD into three categories
because absolute frequencies for certain categories were
very small and this would create problems in the multi-
variate analysis.
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The sample of 151 women in the case group and 154
in the control group were evaluated as having a 80 %
power to detect an OR (Odds Ratio) of 2 at a 0.05 sig-
nificance level for an exposure (dense breast according
to BIRADS score) expected the control group equal to
40 %. The proportional odds were tested using the Brant
test. For both groups of cases, the proportional odds as-
sumption was verified (chi square = 2.316 p = 0.678 in
the case group; chi square = 4.106 p = 0.392 in the con-
trol group).
Continuous variables were presented as mean ± Standard
Deviation (SD), and differences were evaluated by the
Student’s t test or the Mann–Whitney test. Categorical
variables were expressed as count and percentages. To
assess the association the chi-square test or Fisher’s
exact test were used as appropriate. Multivariate analyses
(ordered logistic regression and binary logistic regression)
were used to calculate ORs, including interacting or con-
founding effects of age, BMI, family history and age at me-
narche. All tests were two-tailed, and p-value <0.05 was
considered significant. All computations were carried out
using STATA v.12.
Results
Mean age of the 151 case group patients was 38.96 ± 2.88
and mean BMI was 23.15 ± 3.88. All were affected by
primary infertility: 57.8 % sine causa, 37 % ovulatory fac-
tors and 5.2 % endometriosis. Of this group, 6.6 % had a
positive family history of breast cancer and 40.4 % had re-
ceived hormonal contraceptive therapy (HCT). Mean age
at menarche was 12.34 ± 1.49.
Mean age of the 154 control group patients was
41.79 ± 3.09 and mean BMI was 22.58 ± 3.05. Of this
group 52 % had a positive family history of breast can-
cer and 44.2 % had received contraceptive therapy.
Mean age at menarche was 12.44 ± 1.47.
The mean age difference between the two groups was
statistically significant, but difference in BMI values was
not statistically significant (Table 1).
All mammograms included in the study were classified
as P (perfect) or G (good) according to the PGMI evalu-
ation system.
Evaluation of mammographic features showed that
33.1 % (50/151) of case group patients and 46.1 % (71/154)
of control group patients were classified BIRADS-1/BIR-
ADS-2; p < 0.05, and that 66.9 % (101/151) of case group
patients and 53.9 % (83/154) of control group patients were
classified BIRADS-3/BIRADS-4; p < 0.05 (Table 2).
Adjusted OR for the case group vs. the control group in
categories BIRADS-3/BIRADS-4 was 1.78 (95 % CI:
1.10-2.89); p = 0.02 (Table 3).
Boyd classification of mammographic features showed
that 19.2 % (29/151) of case group patients and 22.7 %
(35/154) of control group patients were assigned to cat-
egories A and B (p > 0.05); 27.2 % (41/151) of case group
patients and 45.5 % (70/154) of control group patients
were assigned to categories C and D (p < 0.05); 53.6 %
(81/151) of case group patients and 31.8 % (49/154) of
control group patients were assigned to categories E and
F; (p < 0.05) (Table 2).
Adjusted OR for the case group vs. the control group
in Boyd categories E and F was 2.05 (95 % CI: 1.07-3.93)
(p = 0.03). Adjusted OR for categories C and D vs. cat-
egories A and B was 0.75 (95 % CI:0.39-1.46) (p = 0.39)
(Table 4).
Discussion
Breast cancer is the most common malignancy in
women and a leading cause of cancer-related death
worldwide [15, 19]. In the absence of a known prevent-
able cause of breast cancer, the single most important
factor in reducing mortality is early detection. Mammog-
raphy and ultrasound are currently the techniques of
choice for breast cancer evaluation. The sensitivity of
mammography varies and is influenced by breast dens-
ity. Dense fibroglandular tissue is the most important in-
herent limitation of mammography in the diagnosis of
breast cancer [12], and dense breast tissue is considered
a risk factor in the subsequent development of breast
cancer [19].
Mammographic breast density is very often linked to
cancer due to masking bias, as malignant lesions have
the same x-ray attenuation properties as fibroglandular
tissue [19, 20]. In our previous study, we analysed a se-
lected population of women with primary infertility and
Table 1 Characteristics of the two study groups
Case group
(151 women)
Control group
(154 women)
p
BMI (kg/m2) (mean ± SD) 23.15 ± 3.88 22.58 ± 3.05 0.591
Age (mean ± SD) 38.96 ± 2.88 41.79 ± 3.09 <0.001
Family history of
Breast Cancer (%) No.
(6.6 %) 10 (52 %) 80 <0.0001
Previous use of HCT (%) No. (40.4 %) 61 (44.2 %) 68 0.308
Age at menarche (mean ± SD) 12.34 ± 1.49 12.44 ± 1.47 0.148
Table 2 Evaluation of mammographic features using the
BIRADS and Boyd systems
Case group
(151 women)
Control group
(154 women)
p
BIRADS-1/BIRADS-2 33.1 % 46.1 % 0.026
BIRADS-3/BIRADS-4 66.9 % 53.9 % 0.026
Boyd Cat. A/B 19.2 % 22.7 % NS
Boyd Cat. C/D 27.2 % 45.5 % <0.0001
Boyd Cat. E/F 53.6 % 31.8 % <0.0001
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we found that 68 % of patients had dense breasts ac-
cording to the BIRADS score [17]. The study in question
presented some limitations: it lacked a control group
and used only the BIRADS system, which was originally
a morphological assessment.
This is the first study that has investigated breast density
of infertile women referred to assisted conception services
and compared the outcome with a group of premeno-
pausal parous women aged ≥35. In this study, two
methods were used to assess mammographic density, BIR-
ADS and Boyd, and both confirmed previous results for
the infertile women. The percentage of dense breasts in
the group of women with primary infertility was higher
using both BIRADS (66.9 % vs. 53.9 %, p < 0.05) and Boyd
(53.6 % vs. 31.8 %, p < 0.05) compared to parous woman.
One of the most important limitations of this study is the
difference in the mean age between the two groups. Mean
age of the control group was higher, because mammo-
graphic screening and other preventive measures before
age 40 are not recommended except in women at high
risk of breast cancer [12]. According to the FONCAM
guidelines, the first diagnostic approach recommended be-
fore age 40 is clinical examination. If suspicious signs for
malignancy are found, ultrasound is performed, followed
by a mammogram if necessary [12]. Therefore, from the
database of the Department of Radiology, we selected
women who had undergone mammography examinations
for various reasons. This caused a slight difference be-
tween the mean age in the two study groups. Sensitivity
and specificity of mammographic evaluation is lower in
younger women than in older women because younger
woman more often have dense breast tissue [21]. There-
fore, we used multivariate analysis to take into account
potential confounding factors, such as age, BMI and fam-
ily history. Nevertheless, dense breast tissue was more fre-
quent in the case group as established according to the
Boyd and BIRADS systems. The role of nulliparity as a
risk factor for breast density has been discussed in several
studies [13, 22]. There might be a biological relationship
between parity and the risk of breast cancer given that
high breast density is present in most nulliparous women
[10, 14, 17]. Furthermore, nulliparous women often
present a large quantity of undifferentiated epithelial
breast tissue, which is more susceptible to carcinogenetic
stimuli such as endogenous and exogenous female hor-
mones [23].
Conclusions
In conclusion, this study confirms that patients with pri-
mary infertility have denser breast tissue and may be at
risk for breast cancer.
The Boyd and BIRADS systems were not developed to
quantify the risk, but to allow an interpreting radiologist
to indicate the level of concern that a cancer lesion in
the breast might be missed on mammography due to
masking by dense tissue.
Infertile women with high BIRADS or Boyd scores,
who undertake IVF treatment, should be investigated
with appropriate diagnostic tools including magnetic
resonance imaging (MRI) to reduce masking bias.
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BMI obese 0.45 0.10 2.06 0.31
Age 35-39 3.99 1.26 12.61 0.02
Age ≥40 2.46 0.77 7.91 0.13
BIRADS 3/4 1.78 1.10 2.89 0.02
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P value
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BMI normal 1.42 0.42 4.98 0.59
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BMI obese 0.45 0.09 2.45 0.32
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